Jim Cramer: We Don't Know What the Antibody Test Does

Jim Cramer weighs in on antibody tests.
Publish date:

Roche, the Swiss drug giants, got an emergency go-ahead from the Food and Drug Administration for its Covid-19 antibody test over the weekend, as the U.S. clocked in well over 1.1 million total known infections from the novel coronavirus and close to 68,000 deaths. 

The FDA used its "Emergency Use Authorization" to approve the tests, known as the Elecsys Anti-SARS-CoV-2 antibody test. 

The company says the so-called serology test has a "specificity" greater than 99.8% and sensitivity of 100%, within 14 days after confirmation.

"Roche has already started shipping the new antibody test to leading laboratories globally and will ramp up production capacity to high double-digit millions per month to serve health care systems in countries accepting (accepting European approvals) as well as the U.S.," said the company in a statement.

But, is an antibody test enough?

Watch the full video above for Jim Cramer's full take.

Want to know what Cramer and his team at Action Alerts PLUS are thinking about the markets and the stocks they're watching? Sign up on Action Alerts PLUS for more.

Cramer and the team are weighing in on what members need to know about the coronavirus pandemic's impact on the market. Here's how you can recap his entire April show.

Watch More of the Latest Videos on TheStreet and Jim Cramer